Camaro1093 Stocks!

[mlkrborn]

098 NOW AFTER SET BACK on march 18 2010. Anyone in?
Biopharma Stock Alert for A.P. Pharma Inc. Issued by StockPreacher

DALLAS, March 22, 2010
GLOBE NEWSWIRE
StockPreacher.com announces an investment report featuring A.P. Pharma Inc. (Nasdaq:APPA). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: http://www.stockpreacher.com/n/APPA

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher

A.P. Pharma Inc. (APPA) is a specialty pharmaceutical company focused on developing pharmaceutical products using its Biochronomer polymer-based drug delivery technology. The Company's primary focus is on its lead product candidate, APF530, which completed a pivotal phase III clinical trial for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the year ended December 31, 2008.

Message Board Search for APPA: http://www.boardcentral.com/boards/APPA

In the report, the analyst notes:

"APPA's net loss for the fourth quarter of 2009 was $1.9 million, or $0.05 per share, compared with a net loss of $3.9 million, or $0.13 per share, for the fourth quarter of 2008. For the full year 2009, the Company's net loss was $10.0 million, or $0.31 per share, versus a net loss of $23.1 million, or $0.75 per share, for 2008. The improved operating results in both the quarter and the year ended December 31, 2009, were principally due to APPA's decision to suspend, for the time being, development of its other product candidates in order to focus its resources on the submission and approval of the NDA for APF530, as well as other cost containment initiatives undertaken by the Company.

"APPA recently said U.S. health regulators did not approve its experimental drug for the treatment of nausea and vomiting induced by chemotherapy (CINV), citing concerns regarding the drug's administration system, and asked for more studies. The specialty pharmaceutical Company does not expect the commercial launch of the drug, APF530, in 2010, based on the expected time needed for a resubmission."

To read the entire report visit: http://www.stockpreacher.com/n/APPA

See what investors are saying about APPA at penny stock forum

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly owned by BlueWave Advisors, LLC. StockPreacher.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.

CONTACT: StockPreacher.com

Nic Lesmeister

(469)-252-3505

[e-mail]